Long-Term Data Reported for Ulcerative Colitis Drug Adalimumab

the MPR take:

Adalimumab is a tumor necrosis factor-alpha blocker indicated for the treatment of moderately-to-severely active ulcerative colitis (UC) to induce and sustain clinical remission in adults who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine or 6-MP.  Based on placebo-controlled trials, the safety and efficacy of adalimumab therapy in UC patients has been reported up to Week 52. New research published in The American Journal of Gastroenterology now reports on study data for up to 4 years of adalimumab treatment. Based on the findings in this long-term data, researchers report that remission, mucosal healing, and improvement in quality of life were all maintained in UC patients treated with adalimumab therapy for up to 4 years.  Also, rates of colectomy and hospitalization (both UC-related and all-cause) were lower in patients treated with long-term adalimumab. No new safety risks were seen with long-term therapy.

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcer
Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcer

The safety and efficacy of adalimumab for patients with moderately to severely active ulcerative colitis (UC) has been reported up to Week 52 from the placebo-controlled trials ULTRA (Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab) 1 and 2. Up to 4 years of data for adalimumab-treated patients from ULTRA 1, 2, and the open-label extension ULTRA 3 are presented.

READ FULL ARTICLE From Nature